Medical Education

Office: 1002 910 MADISON BUILDING
MEMPHIS TN 381632242
Tel: (901) 448-4591


  1. Zmijewski, MA, Li, W, Zjawiony, JK, Sweatman, TW, Chen, J, Miller, DD, Slominski, AT. Photo-conversion of two epimers (20R and 20S) of pregna-5,7-diene-3beta, 17alpha, 20-triol and their bioactivity in melanoma cells. Steroids, 74 (2), 218-28, 2009.
  2. Zmijewski, MA, Li, W, Zjawiony, JK, Sweatman, TW, Chen, J, Miller, DD, Slominski, AT. Synthesis and photo-conversion of androsta- and pregna-5,7-dienes to vitamin D3-like derivatives. Photochem Photobiol Sci, 7 (12), 1570-6, 2008.
  3. Zbytek, B, Janjetovic, Z, Tuckey, RC, Zmijewski, MA, Sweatman, TW, Jones, E, Nguyen, MN, Slominski, AT. 20-Hydroxyvitamin D3, a product of vitamin D3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol, 128 (9), 2271-80, 2008.
  4. Hofmann, PA, Israel, M, Koseki, Y, Laskin, J, Gray, J, Janik, A, Sweatman, TW, Lothstein, L. N-Benzyladriamycin-14-valerate (AD 198): a non-cardiotoxic anthracycline that is cardioprotective through PKC-epsilon activation. J Pharmacol Exp Ther, 323 (2), 658-64, 2007.
  5. Lothstein, L, Savranskaya, L, Sweatman, TW. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity. Leuk Res, 31 (8), 1085-95, 2007.
  6. Fischer, TW, Zmijewski, MA, Zbytek, B, Sweatman, TW, Slominski, RM, Wortsman, J, Slominski, A. Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Int J Oncol, 29 (3), 665-72, 2006.
  7. Fischer, TW, Sweatman, TW, Semak, I, Sayre, RM, Wortsman, J, Slominski, A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J, 20 (9), 1564-6, 2006.
  8. Lothstein, L, Savranskaya, L, Barrett, CM, Israel, M, Sweatman, TW. N-benzyladriamycin-14-valerate (AD 198) activates protein kinase C-delta holoenzyme to trigger mitochondrial depolarization and cytochrome c release independently of permeability transition pore opening and Ca2+ influx. Anticancer Drugs, 17 (5), 495-502, 2006.
  9. Fischer, TW, Zbytek, B, Sayre, RM, Apostolov, EO, Basnakian, AG, Sweatman, TW, Wortsman, J, Elsner, P, Slominski, A. Melatonin increases survival of HaCaT keratinocytes by suppressing UV-induced apoptosis. J Pineal Res, 40 (1), 18-26, 2006.
  10. Bilyeu, JD, Panta, GR, Cavin, LG, Barrett, CM, Turner, EJ, Sweatman, TW, Israel, M, Lothstein, L, Arsura, M. Circumvention of nuclear factor kappaB-induced chemoresistance by cytoplasmic-targeted anthracyclines. Mol Pharmacol, 65 (4), 1038-47, 2004.
  11. Panta, GR, Kaur, S, Cavin, LG, Cortés, ML, Mercurio, F, Lothstein, L, Sweatman, TW, Israel, M, Arsura, M. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol, 24 (5), 1823-35, 2004.
  12. Roaten, JB, Kazanietz, MG, Caloca, MJ, Bertics, PJ, Lothstein, L, Parrill, AL, Israel, M, Sweatman, TW. Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity. Mol Cancer Ther, 1 (7), 483-92, 2002.
  13. Barrett, CM, Lewis, FL, Roaten, JB, Sweatman, TW, Israel, M, Cleveland, JL, Lothstein, L. Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther, 1 (7), 469-81, 2002.
  14. Lothstein, L, Israel, M, Sweatman, TW. Anthracycline drug targeting: cytoplasmic versus nuclear--a fork in the road. Drug Resist Updat, 4 (3), 169-77, 2001.
  15. Roaten, JB, Kazanietz, MG, Sweatman, TW, Lothstein, L, Israel, M, Parrill, AL. Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta. J Med Chem, 44 (7), 1028-34, 2001.
  16. Lothstein, L, Suttle, DP, Roaten, JB, Koseki, Y, Israel, M, Sweatman, TW. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochem Pharmacol, 60 (11), 1621-8, 2000.
  17. Wani, MK, Koseki, Y, Yarber, RH, Sweatman, TW, Ahmed, A, Samant, S, Hengesteg, A, Israel, M, Robbins, KT. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope, 110 (12), 2026-32, 2000.
  18. Sweatman, TW, Seshadri, R, Israel, M. Pharmacology of N-benzyladriamycin-14-valerate in the rat. Cancer Chemother Pharmacol, 43 (5), 419-26, 1999.
  19. Pawlik, CA, Israel, M, Sweatman, TW, Lothstein, L. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities. Oncol Res, 10 (4), 209-17, 1998.
  20. Lothstein, L, Rodrigues, PJ, Sweatman, TW, Israel, M. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anticancer Drugs, 9 (1), 58-66, 1998.
  21. Han, G, Israel, M, Seshadri, R, Dalton, JT, Sweatman, TW. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat. Cancer Chemother Pharmacol, 37 (5), 472-8, 1996.
  22. Lothstein, L, Koseki, Y, Sweatman, TW. P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198). Anticancer Drugs, 5 (6), 623-33, 1994.
  23. Lothstein, L, Hosey, LM, Sweatman, TW, Koseki, Y, Dockter, M, Priebe, W. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance. Oncol Res, 5 (6-7), 229-34, 1993.
  24. Lothstein, L, Sweatman, TW, Dockter, ME, Israel, M. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res, 52 (12), 3409-17, 1992.
  25. Lothstein, L, Wright, HM, Sweatman, TW, Israel, M. N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells. Oncol Res, 4 (8-9), 341-7, 1992.
  26. Sweatman, TW, Parker, RF, Israel, M. Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study. Cancer Chemother Pharmacol, 28 (1), 1-6, 1991.
  27. Kashfi, K, Israel, M, Sweatman, TW, Seshadri, R, Cook, GA. Inhibition of mitochondrial carnitine palmitoyltransferases by adriamycin and adriamycin analogues. Biochem Pharmacol, 40 (7), 1441-8, 1990.
  28. Sweatman, TW, Seshadri, R, Israel, M. Metabolism and elimination of rhodamine 123 in the rat. Cancer Chemother Pharmacol, 27 (3), 205-10, 1990.
  29. Sweatman, TW, Lokich, JJ, Israel, M. Clinical pharmacology of continuous infusion doxorubicin. Ther Drug Monit, 11 (1), 3-9, 1989.
  30. Israel, M, Sweatman, TW, Seshadri, R, Koseki, Y. Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol, 25 (3), 177-83, 1989.
  31. Israel, M, Seshadri, R, Koseki, Y, Sweatman, TW, Idriss, JM. Amelioration of adriamycin toxicity through modification of drug-DNA binding properties. Cancer Treat Rev, 14 (3-4), 163-7, 1987.